Parasitic Diseases: Clinical Trials

423 trials for Parasitic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

345 completed, 21 terminated, 18 unknown, 12 not yet recruiting. 423 Phase 1, 87 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1423Completed 345, Terminated 21, Unknown 18, Not yet recruiting 12, Withdrawn 12, Recruiting 8, Active not recruiting 5, Suspended 2
Phase 287Completed 68, Unknown 6, Terminated 5, Withdrawn 3, Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Suspended 1

Follow Parasitic Diseases: new trials by email Literature Review of Parasitic Diseases trials Research Report on Parasitic Diseases

Trials (filtered) newest first · largest first

All 423 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline - Malaria (Plasmodium Falciparum)
Phase 1Not yet recruitingSanaria Inc.452027-03-012026-07-31
HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation
ivermectin infant formula preparation, Standard ivermectin 3mg tablet - Scabies
Phase 1SuspendedMurdoch Childrens Research Institute522027-01-012026-10-09
Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model
Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria
Phase 1 / Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)2202026-11-232026-11-18
Malaria CVD 36000; Gates INV090205
PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo - Malaria (Plasmodium Falciparum)
Phase 1Not yet recruitingUniversity of Maryland, Baltimore322026-11-012026-09-09
A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults
Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax) - Malaria
Phase 1Not yet recruitingUniversity of Oxford242026-11-012026-08-05
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine
Phase 1Not yet recruitingGuangzhou Patronus Biotech Co., Ltd.722026-10-012026-10-22
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
Cohort 1 low dose lotilaner with a high-fat meal, Cohort 1 low dose placebo with a high-fat meal, Cohort 2 high dose lotilaner in fasted state - Malaria
Phase 1RecruitingMedicines for Malaria Venture752026-09-142026-09-24
Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)
PfSPZ Vaccine, PfSPZ Diluent, Normal Saline - Malaria
Phase 1WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2026-09-142026-09-16
Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection
Artemisia Annua Leaf, Centaurii herba - Asymptomatic P.Falciparum Malaria
Phase 1Not yet recruitingCentre de Recherche Médicale de Lambaréné202026-09-012026-09-15
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
MMV371, Placebo for MMV371 - Malaria (Plasmodium Falciparum), Malaria Falciparum
Phase 1Not yet recruitingMedicines for Malaria Venture802026-09-012026-04-23
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
GSK4425689A SC, GSK4425689A IV, Placebo - Malaria, Falciparum
Phase 1RecruitingGlaxoSmithKline402026-07-272026-10-05
Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years
Midazolam (MDZ), GSK3772701 - Malaria, Falciparum
Phase 1CompletedGlaxoSmithKline202026-06-262026-09-30
A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
SUM-101, CHMI, Verorab® - Malaria Fever
Phase 1WithdrawnEuropean Vaccine Initiative2026-03-202026-09-11
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Normal Saline (Placebo), PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8) - Malaria Falciparum
Phase 1RecruitingSanaria Inc.422026-03-122026-11-03
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
MILTEFOSINE gel - Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American
Phase 1Not yet recruitingUniversidad Industrial de Santander152026-01-012025-09-08
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
R21, RH5.1, R78C - Malaria,Falciparum
Phase 1Active not recruitingUniversity of Oxford562025-09-152026-10-21
Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults
Trichuris trichiura Egg Inoculum - Whipworm, Trichuriasis
Phase 1RecruitingGeorge Washington University182025-09-102026-06-04
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory, Placebo - Malaria Vivax
Phase 1Not yet recruitingFederal University of Minas Gerais482025-09-012025-09-15
First-in-Human Trial of Oral AN2-502998
AN2-502998, Placebo - Healthy Volunteers
Phase 1CompletedAN2 Therapeutics, Inc722025-08-042026-04-30
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
SUM-101 - Malaria,Falciparum
Phase 1CompletedEuropean Vaccine Initiative392025-08-012026-09-11

Showing 20 of 423. Sign in to see all of them.

Narrower conditions

Malaria (265)  ·  Malaria, Falciparum (137)  ·  Malaria, Vivax (19)  ·  Leishmaniasis (15)  ·  Ancylostomiasis (12)  ·  Hookworm Infections (11)  ·  HIV Infections (10)  ·  Leishmaniasis, Cutaneous (10)  ·  Parasitemia (10)  ·  Chagas Disease (8)  ·  Neglected Diseases (8)  ·  Schistosomiasis (8)  ·  Infections (7)  ·  Acquired Immunodeficiency Syndrome (6)

Broader conditions

Infections (416)  ·  Protozoan Infections (371)  ·  Vector Borne Diseases (369)  ·  Mosquito-Borne Diseases (326)  ·  Malaria (59)  ·  Euglenozoa Infections (37)  ·  Helminthiasis (37)  ·  Skin Diseases (32)  ·  Skin Diseases, Infectious (32)  ·  Skin Diseases, Parasitic (32)  ·  Skin and Connective Tissue Diseases (32)  ·  Pathological Conditions, Signs and Symptoms (30)  ·  Pathologic Processes (25)  ·  Nematode Infections (22)

Interventions

Saline Solution (19)  ·  Artemether, Lumefantrine Drug Combination (13)  ·  Primaquine (12)  ·  Matrix-M (11)  ·  Chloroquine (9)  ·  fanasil, pyrimethamine drug combination (8)  ·  Aluminum Hydroxide (7)  ·  Rabies Vaccines (7)  ·  Sodium Chloride (7)  ·  artefenomel (7)  ·  Artesunate (6)  ·  Hepatitis B Vaccines (6)  ·  Ivermectin (6)  ·  Pyrimethamine (6)  ·  piperaquine (6)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (66)  ·  University of Oxford (55)  ·  Medicines for Malaria Venture (44)  ·  U.S. Army Medical Research and Development Command (25)  ·  Sanaria Inc. (23)  ·  GlaxoSmithKline (18)  ·  Baylor College of Medicine (11)  ·  Drugs for Neglected Diseases (11)  ·  Novartis Pharmaceuticals (8)  ·  Access to Advanced Health Institute (AAHI) (6)  ·  European Vaccine Initiative (6)  ·  Radboud University Medical Center (6)  ·  Swiss Tropical & Public Health Institute (6)  ·  African Malaria Network Trust (5)  ·  Bayer (5)

Countries

United States (117)  ·  United Kingdom (62)  ·  Australia (29)  ·  Mali (28)  ·  Burkina Faso (16)  ·  Tanzania (15)  ·  Netherlands (12)  ·  Brazil (11)  ·  Gabon (11)  ·  Germany (9)  ·  Kenya (9)  ·  Colombia (8)  ·  France (8)  ·  Switzerland (8)  ·  Thailand (8)

Top investigators

Patrick E Duffy, M.D. (8)  ·  James McCarthy, Prof (6)  ·  Adrian VS Hill, D.Phil, FRCP (5)  ·  Adrian V S Hill, MD (4)  ·  David Diemert, MD (4)  ·  Ulrike Lorch, MD FRCA FFPM (4)  ·  Adrian V Hill, DPhill FRCP (3)  ·  Adrian VS Hill (3)  ·  Adrian VS Hill, MA, BM BCh, DPhil, DM (3)  ·  Ayola Adegnika, MD (3)  ·  Blaise Genton, MD PhD (3)  ·  David J Diemert, MD (3)

Results publications

PMID 39787798, PMID 31932368, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 28464026, PMID 29389671, PMID 32239164, PMID 32275867, PMID 33717176, PMID 34179977, PMID 34194041, PMID 34265407, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 10190913, PMID 10501745, PMID 11353640, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17925866, PMID 17940609, PMID 18060072, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18378716, PMID 18396361, PMID 18419347, PMID 18545693, PMID 18612426, PMID 18698359, PMID 18930565, PMID 19093004, PMID 19390585, PMID 19569965, PMID 19607731

NIH funding

2015 (4), 2019 (4), 2017 (3), 2016 (2), 2018 (2), U01CI000211 (2), 2014 (1), 2023 (1), 5UM1AI148373-03 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01AI041735 (1), R01HL086488 (1), R01HL130763 (1)